Trial reportThe European respiratory journal2018
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
Trial report in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effect of CALIPER-derived parameters for idiopathic pulmonary fibrosis in predicting prognosis, progression, and mortality: a systematic review.European radiology · 2023Pooled it
- The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2018Pooled it
- Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.American journal of respiratory and critical care medicine · 2026Trial
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.The European respiratory journal · 2023Trial
- Prevent or Treat? Evaluating a Delayed Treatment With Nintedanib After Murine Orthotopic Tracheal Transplantation.Transplantation direct · 2026Article
- Regioselective Glycosylation of Demethylbellidifolin by Glycosyltransferase AbCGT Yields Potent Anti-Renal Fibrosis Compound.Molecules (Basel, Switzerland) · 2026Article
- Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis.ERJ open research · 2026Article
- Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now.American journal of respiratory and critical care medicine · 2024Article
- Review
- Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment Management, and Outcomes.Life (Basel, Switzerland) · 2023Article
- Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study.BMC medical imaging · 2022Observational
- Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis.Contemporary clinical trials communications · 2021Article
- Treatment of Idiopathic Pulmonary Fibrosis.Cureus · 2021Review
- Review
- Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.Respiratory research · 2021Observational
- Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2020Article
- Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.The open respiratory medicine journal · 2020Article
- Article
- Management of Idiopathic Pulmonary Fibrosis.The Annals of pharmacotherapy · 2019Review
- Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.Internal medicine (Tokyo, Japan) · 2019Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC)
Indexed as
Identifiers
29946007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.